NBC 10 News featured Mammogen CEO Elizabeth Cormier-May in its coverage of the evolving landscape of blood-based cancer detection and an upcoming FDA advisory committee review of GRAIL’s Galleri test. Cormier-May shared her perspective on the significance of liquid biopsy technology and discussed how Mammogen’s approach differs by focusing specifically on earlier breast cancer detection. The story also highlights Mammogen’s blood-based test and its potential role in supporting women who may need additional testing following their annual mammogram. Read the full article on NBC 10 News →

Explore RNA-powered diagnostics for breast cancer. Get checked today for better early detection!

Read our interview with Liz Cormier-May on Mammogen's RNA diagnostics for women's health. Empower yourself with knowledge today.

Learn how Mammogen uses liquid biopsy for early breast cancer detection. Support women's health with innovative diagnostics.

Marty Keiser & Elizabeth Cormier-May discuss Mammogen's innovations in breast imaging on the OffScrip Media podcast. Tune in for insights!